Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Boundless Bio, Inc. - Common Stock (NQ:BOLD)

1.450 -0.060 (-3.97%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Boundless Bio, Inc. - Common Stock

Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
From Boundless Bio, Inc.
Via GlobeNewswire
Boundless Bio to Participate in the Leerink Global Healthcare Conference
From Boundless Bio, Inc.
Via GlobeNewswire
Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer
- Dr. Doebele has over 15 years of oncology drug development experience as a public company Chief Medical Officer and clinical researcher at leading cancer centers - 
From Boundless Bio, Inc.
Via GlobeNewswire
Boundless Bio Announces Pipeline and Leadership Updates
From Boundless Bio, Inc.
Via GlobeNewswire
Boundless Bio to Participate in the Piper Sandler Healthcare Conference
From Boundless Bio, Inc.
Via GlobeNewswire
Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights
From Boundless Bio, Inc.
Via GlobeNewswire
Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference
From Boundless Bio, Inc.
Via GlobeNewswire
Boundless Bio Announces Departure of Chief Financial Officer
From Boundless Bio, Inc.
Via GlobeNewswire
Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference
From Boundless Bio, Inc.
Via GlobeNewswire
Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results
From Boundless Bio, Inc.
Via GlobeNewswire
Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Boundless Bio
Via Business Wire
Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights
From Boundless Bio
Via Business Wire
Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024
From Boundless Bio
Via Business Wire
Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications
From Boundless Bio
Via Business Wire
Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024
From Boundless Bio
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.